These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25628060)

  • 41. New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):241-2. PubMed ID: 12113038
    [No Abstract]   [Full Text] [Related]  

  • 42. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
    Hurwitz HI; Lyman GH
    J Clin Oncol; 2012 Feb; 30(6):580-1. PubMed ID: 22253468
    [No Abstract]   [Full Text] [Related]  

  • 43. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
    Rebesco B; Cantagalli E; Amalfitano ME
    Tumori; 2005; 91(6):suppl 1-10. PubMed ID: 16457161
    [No Abstract]   [Full Text] [Related]  

  • 44. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
    Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Short-term therapeutic effect of Endostar combined with chemotherapy for advanced colorectal cancer: a meta-analysis].
    Pan Y; Jiao G
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):270-4. PubMed ID: 24589611
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Gleaning from the American Oncology Congress. A new standard in colorectal carcinoma].
    MMW Fortschr Med; 2002 Oct; 144(41):61. PubMed ID: 12474374
    [No Abstract]   [Full Text] [Related]  

  • 47. [ASCO 2005: Progression with oxaliplatin in the treatment of colorectal neoplasms].
    Longo F; Mansueto G
    Tumori; 2005; 91(3):suppl 1-12. PubMed ID: 16206661
    [No Abstract]   [Full Text] [Related]  

  • 48. Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
    Pazdur R
    J Gastroenterol; 2000; 35 Suppl 12():131. PubMed ID: 10779234
    [No Abstract]   [Full Text] [Related]  

  • 49. [Adjuvant and palliative therapy for colorectal carcinoma].
    Heike M; Wölfel T; Meyer zum Büschenfelde KH; Knuth A; Dippold WG
    Dtsch Med Wochenschr; 1994 May; 119(21):778-85. PubMed ID: 7514969
    [No Abstract]   [Full Text] [Related]  

  • 50. When less is more: maintenance therapy in colorectal cancer.
    Hubbard JM; Grothey A
    Lancet; 2015 May; 385(9980):1808-10. PubMed ID: 25862518
    [No Abstract]   [Full Text] [Related]  

  • 51. S-1: another oral agent for patients with colorectal cancer.
    Benson AB
    Lancet Oncol; 2013 Dec; 14(13):1244-5. PubMed ID: 24225156
    [No Abstract]   [Full Text] [Related]  

  • 52. Explaining the unexplainable: EGFR antibodies in colorectal cancer.
    Grothey A; Lenz HJ
    J Clin Oncol; 2012 May; 30(15):1735-7. PubMed ID: 22473160
    [No Abstract]   [Full Text] [Related]  

  • 53. The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1999; 46(2):132-9. PubMed ID: 10466439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TAS-102 in metastatic colorectal cancer.
    Burki TK
    Lancet Oncol; 2018 Jan; 19(1):e18. PubMed ID: 29249306
    [No Abstract]   [Full Text] [Related]  

  • 55. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
    Goldstein DA; El-Rayes BF
    Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is the pooled analysis of the north central cancer treatment group phase III trials N9741 and N9841 biased?
    Mandalà M; Grosso F
    J Clin Oncol; 2012 May; 30(15):1894-5; author reply 1895. PubMed ID: 22473158
    [No Abstract]   [Full Text] [Related]  

  • 57. [Successes in late solid tumors. New therapy offer].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):71. PubMed ID: 15624667
    [No Abstract]   [Full Text] [Related]  

  • 58. Role of oral chemotherapy in colorectal cancer.
    Donehower RC
    Oncology (Williston Park); 2000 Nov; 14(11A):243-5. PubMed ID: 11195416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Another effective chemotherapy combination for colorectal cancer.
    Oncology (Williston Park); 1988 Nov; 2(11):68. PubMed ID: 3275045
    [No Abstract]   [Full Text] [Related]  

  • 60. Phase III aflibercept-chemotherapy combination trial shows benefit in previously treated metastatic colorectal cancer patients.
    Oncology (Williston Park); 2011 Nov; 25(12):1213. PubMed ID: 22229217
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.